The CAPItello-291 Phase III clinical trial reported that Capivasertib combined with fulvestrant significantly prolonged progression-free survival in HR-positive advanced breast cancer patients, some of whom had disease progression after CDK4/6 inhibitor treatment 54. This evidence concerns the gene CDK4 and breast carcinoma.